Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-CD16/IL-15/anti-CD33 trispecific natural Killer cell engager GTB-3650

A trispecific natural killer (NK) cell engager comprised of an anti-cluster of differentiation 16 (CD16; FcgammaRIII) camelid nanobody, human interleukin-15 (IL-15), and an anti-CD33 single-chain variable fragment (scFv), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD16/IL-15/anti-CD33 trispecific NK cell engager GTB-3650 targets and binds to CD33 expressed on tumor cells and simultaneously binds to the activating CD16 Fc receptor expressed on NK cells, thereby bringing CD33-expressing tumor cells and NK cells together. This induces NK cell cytotoxicity specifically against CD33-expressing tumor cells. The cytokine IL-15 promotes NK cell proliferation, activity, survival and expansion. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and is overexpressed on myeloid leukemia cells.
Synonym:anti-CD16/IL-15/anti-CD33 trispecific killer engager GTB-3650
anti-CD16/IL-15/anti-CD33 trispecific NK cell engager GTB-3650
anti-CD16/IL-15/anti-CD33 trispecific NK engager GTB-3650
anti-CD16/IL15/anti-CD33 TriKE GTB-3650
Code name:GTB 3650
GTB-3650
GTB3650
Search NCI's Drug Dictionary